ProMetic and Sartorius Stedim Biotech Join Forces
News May 01, 2013
ProMetic Life Sciences Inc. announced the expansion of its existing strategic collaboration with Sartorius Stedim Biotech ("SSB") to include a contribution of equipment to ProMetic's plasma purification facility as well as an agreement for the co-commercialization of PPPSTM on a global basis.
Pursuant to the agreement, SSB will provide filtration equipment and other consumables to be integrated in ProMetic's plasma purification plant, which is set to be operational in the fourth quarter of 2013. SSB's strategic contribution represents a significant investment over the next 3 years as plasma derived products manufactured in the GMP facility undergo regulatory approval. The agreement also confirms SSB as a preferred supplier of filtration equipment and consumables for ProMetic's PPPSTM licensees. SSB filtration equipment and consumables will be offered as an integral part of ProMetic's offering of plasma purification turnkey processes.
Dr. Uwe Gottschalk, Vice-President of Marketing for Purification Technologies at SSB stated, "The successful scale-up of the PPPSTM technology represents a unique opportunity to provide the plasma purification industry with a novel turnkey process, which achieves significantly improved yields and purity, while using a smaller plant footprint compared with current industry practices. We are happy to contribute our globally recognized engineering and technical expertise to our expanded partnership. We believe this will facilitate and accelerate market penetration".
ProMetic and SSB have also agreed to expand their co-commercialization efforts of the PPPSTM technology to include respective technological and engineering solution transfers. The expanded global co-commercialization efforts are expected to result in the accelerated penetration of Asia and other emerging markets of a best-in-class, market-ready plasma purification turnkey process.
ProMetic's plasma purification facility created for the development and manufacturing of high-value plasma-derived therapeutics will become a technological showroom for the PPPSTM technology. In this showroom, ProMetic's existing and future clients and partners will experience in a GMP-controlled environment the significant technological benefits provided by the proprietary functional plasma purification process.
"We are excited about the opportunity to take our excellent working relationship with Sartorius Stedim to the next level. We believe that our highly complementary product and process offering, combined with SSB's additional technical and commercial support, will increase market recognition of the significant benefits provided by our proprietary technologies," stated Pierre Laurin, President and CEO of ProMetic.
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE